Answers are grounded in this paper and cite their sources.
Study Objectives: The efficacy and safety of chloral hydrate, used as approved for severe insomnia in the UK, were assessed in a single-arm, open-label, real-world, decentralized clinical trial using contemporary self-reported outcome measures. Methods: Participants (18– 75 years) had clinically significant impairment by severe insomnia (Insomnia Severity Index (ISI) score of 20– 28), and history of behavioral and pharmacological sleep therapy failure. Specialists confirmed the clinical diagnosis and prescribed chloral hydrate (500 mg/5 mL oral solution, 430 or 860 mg daily) for 2 weeks followed by a 4-week follow-up period. Endpoints included change in ISI score from confirmatory diagnosis to treatment end (primary); and sleep measures, health-related quality of life (HRQoL), anxiety, depression, and adverse events (AEs; secondaries). Results: Of the 96 participants (mean baseline ISI, 24.03 [SD, 2.06]), 85 completed the study. Improvements were observed with ISI at treatment end (week 2 mean change was − 10.79 [95% confidence interval, − 12.12, − 9.47]; n=93; week 6 mean change was − 8.04 (95% confidence interval, − 9.13, − 6.95; p < 0.0001; n=85), exceeding the 6-point change considered a minimal clinically important difference. Self-reported sleep measures including Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index, HRQoL, and anxiety shows significant improvements during treatment with some outcomes indicating continued benefit up to 4 weeks post-treatment. Most treatment-related AEs were mild in nature (83.9%, 256/305 events) including wind (73.9%), headache (58.7%), and stomach pain (31.5%). While no events met criteria for serious or severe intensity, seven participants (7.6%) withdrew owing to AEs. Conclusion: Short-term UK-approved chloral hydrate may provide a potential option for severe adult insomnia only when prior treatments have failed. Trial Registration: NCT06053840 ( https://clinicaltrials.gov ); ISRCTN10433315 ( https://www.isrctn.com/ ). Plain Language Summary: Study Rationale Severe insomnia often persists despite behavioral and pharmacological interventions, leaving patients with limited options. Chloral hydrate, an older sedative still approved in the UK, has been less studied with modern outcome tools in routine clinical settings. This study evaluated its use in adults with severe insomnia that had been resistant to previous treatments. Study Impact The RESTORE study found that short-term chloral hydrate treatment was associated with improvements in insomnia severity and related quality-of-life measures, with some effects observed up to four weeks after treatment. Reported adverse events were generally mild, and no serious safety issues were identified during the study period. These findings indicate that chloral hydrate may warrant consideration for selected patients when other treatment options have not been successful whilst recognising the limitations of single arm designs in a real-world setting.
No takes yet. Share an insight, caveat, or question.
Groeger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: